BIOX vs OMEX

The deterministic health scores paint a dire picture: BIOX has a Piotroski F-Score of just 2/9, indicating severe financial weakness. Despite low valuation multiples like a Price/Book of 0.29 and Price/Sales of 0.24, the company is unprofitable with a -17.72% profit margin and deteriorating fundamentals, including -16.40% YoY revenue growth and a -300% YoY EPS decline. Earnings volatility is extreme, with a history of massive negative surprises averaging -268.89% over the last four quarters, and the stock has lost over 85% of its value in five years. While the Forward P/E of 1.88 may appear attractive, it is unsupported by cash flow, balance sheet clarity, or consistent earnings, and the lack of an Altman Z-Score due to missing data further elevates risk.

OMEX exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.23, indicating negative shareholder equity. The company is facing a liquidity crisis with a current ratio of 0.37 and a catastrophic operating margin of -20,662.53%. Revenue has collapsed by 83.3% year-over-year, and the technical trend is fully bearish (0/100). The combination of negative equity, plummeting revenue, and insider selling suggests a high risk of insolvency.